Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns about signs of weakness in sales of its popular diabetes and weight-loss ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Eli Lilly's long, successful history of dominating the diabetes market is more important than any specific drug or pipeline program. This doesn't happen by accident. The company has created and ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.